跟读练习: Accurately Diagnosing the Soft Tissue Sarcoma - 通过YouTube学习英语口语
C2
You know, as our lead surgeon and one of the lead surgeons in the world,
148 句
如果句子过短或过长，请点击 Edit 进行调整。
1
You know, as our lead surgeon and one of the lead surgeons in the world,
2
I think it's always, you know,
3
very important that our surgical colleagues are dramatically involved in the treatment of sarcoma
4
because usually you're the gatekeeper in the entrance of a lot of this.
5
And so, you know, I think it would be good to ask you what your typical workup is for a patient
6
is suspected of having a sarcoma.
7
Sure, thanks, Brian.
8
You know, it's generally a patient will present to a primary care doctor
9
or an orthopedic surgeon or a general surgeon with a mass that is growing,
10
something that is changing, or maybe abdominal distension and discomfort.
11
But like we all learn in medical school,
12
a good history in physical is the first thing we do.
13
If this mass has been there for a long time,
14
it's less likely to be a malignant process or an aggressive malignant process.
15
If it's rapidly changing, the acuity is obviously there and something needs to be done about it.
16
But it's very important to stress the history and physical.
17
I always joke with my trainees that the most important test we order is the history and physical.
18
With that being said, we generally do recommend plain film imaging,
19
radiographs, orthogonal views in the extremity particularly,
20
because that can shed a lot of information in the area of cost containment.
21
If it's completely radiolucent in an extremity film,
22
it is very likely to be lipomatous,
23
well-differentiated liposarcoma at the worst,
24
versus if it has some calcifications on it,
25
the acuity is probably there and that it's a synovial sarcoma or potentially a higher grade liposarcoma,
26
things of that sort.
27
So radiographs are important and they're inexpensive.
28
Beyond that, we do think that advanced imaging is important before any biopsy is done.
29
We generally recommend an MRI in the extremity,
30
sometimes in the pelvis, but often a CT is adequate.
31
And if we really suspect that it's a sarcoma,
32
we prefer getting a chest CT first before any intervention is done.
33
But if you're seeing the patient in the clinic
34
and you're going to do a biopsy in the clinic because it's amenable to that,
35
you can hold off on some of that advanced imaging.
36
But we certainly recommend getting advanced imaging of the primary before any intervention is done.
37
As we all will talk about,
38
the most common site for these metastases is the chest,
39
and so we do think chest imaging is of paramount importance.
40
No, I agree, and I think it's always important to remember that,
41
you know, we hear lots of interesting things and you know,
42
car doors do not cause hematomas unless you're on blood thinners.
43
And so, you know, it's very important to always do that history and physical,
44
because these masses sometimes just get found by car doors.
45
Otherwise, you know, surgeons go and explore in the middle of a sarcoma,
46
and if you don't do these right,
47
I mean, you can get inferior outcomes.
48
And so, I mean, as we're moving through from the history and physical to imaging,
49
I think the next most important thing is really an understanding of diagnosis
50
and grading of these tumors and really what that means.
51
And I think maybe Dr. Jones can give us a little insight about how they approach that.
52
Thank you.
53
So as Dr. Patel mentioned,
54
these are heterogeneous and a complex group of diseases.
55
So it's very important to obtain a clear and accurate histological diagnosis prior to starting treatment.
56
Each histological subtype can have different clinical behavior due to different underlying biology and can also have a different treatment approach.
57
So it's important to have an experienced pathologist make the diagnosis prior to starting treatment.
58
The World Health Organization classification system is generally regarded as the standardized publication for classifying these tumors.
59
and it's very important that newer techniques such as molecular techniques are incorporated into the diagnosis as well.
60
In terms of grading, the most common grading system that's used is the French,
61
so-called French grading system, incorporating three grades,
62
high, intermediate and low, based on tumor differentiation, necrosis and mitotic count.
63
and the grading system has implications in terms of prognosis.
64
I think that's really, really important.
65
And, you know, in the year 2015 with our ability to sequence everybody
66
and our ability to look at all sorts of molecular markers,
67
you know, I think we're into a very complex world and a very rare group of tumors.
68
And so, you know, Jonathan,
69
what is your goals of molecular testing and how do you incorporate that into your practice?
70
Good question.
71
And thank you for the invitation to participate in the panel.
72
And I agree with, certainly with Shreyas and Robin,
73
regarding the complexity of sarcomas.
74
In fact, there's over 200 different types,
75
if you look at the pathology textbooks.
76
And I think that molecular testing is underutilized in the world of sarcoma and that it can help in diagnosis.
77
For instance, there are a number of histologies
78
that have specific genetic abnormalities such as gene amplification and MDM2 and some of the liposarcomas,
79
de-differentiated and well-differentiated.
80
And this testing can not only help make the diagnosis,
81
but there could also be therapeutic relevance.
82
For instance, in the era of targeted therapies,
83
we are now able to pair specific molecular events such as
84
a mutation in a gene called KIT in GI stromal tumor with a therapy such as imatinib
85
or sunitinib or regorafenib and be able to really precisely treat patients based on the molecular rearrangements or abnormalities.
86
And this is particularly pertinent to sarcoma since we have
87
so many histologic subtypes that have a very high frequency of these molecular abnormalities.
88
So, Brian, if I could add a few comments with this too.
89
I think has been well stated.
90
It's a huge number of different tumors.
91
And just like you would never classify carcinomas as one disease,
92
you wouldn't lump breast carcinoma and prostate carcinoma into the same thing.
93
We do that in sarcomas where we have these different diseases.
94
We lump together sarcomas because they're so rare and they can have similar presentations but markedly different genetics and different behavior.
95
And one of the key parts is to make sure,
96
as Robin was saying, that an expert in sarcoma pathologies reviewing the material,
97
especially
98
when it's obtained at a community hospital where pathologists may only
99
see a few cases of these in the course of their career.
100
The hierarchical testing that they do is based not just on the specimen they have,
101
but also based on the presentation of the patient.
102
So it's also very important that the medical
103
and surgical teams are in communication with the pathologist about the location of the tumor,
104
the behavior of the tumor, and those other aspects.
105
So a multidisciplinary approach is really important.
106
And their testing often looks at the shape of the cells first and where it is located,
107
and then that helps drive other testing like immunistic chemistry and other molecular testing.
108
I think we're still very early in the question of the wide-scale genomic testing that's performed either for research
109
or for clinical commercial purposes right now.
110
In our experience, and I think a lot of the other centers are doing this as well,
111
where we've sequenced large panels of genes,
112
we've seen a disappointingly few number of mutations that we didn't already expect in sarcomas.
113
I think it's still a very important area for research,
114
but personally I'm not yet ready to order huge screening panels for genetic mutations,
115
but instead stay focused, as John was just talking about based on the appearance of the tumor,
116
suspected appearance of the tumor,
117
and the possible mutation types.
118
Dr. Yeah, I'd like to,
119
if I may, an illustrative example is in the pediatric realm of a very practical fusion product,
120
you know, the fusion-associated tumors,
121
rhabdomyosarcoma, where historically it's been either in pediatric realm, conventionally alveolar versus embrinal.
122
And now it's actually fusion-driven,
123
and that's the gold standard.
124
And if there's some Pax-Foxo associated tumor that may have some embryonal features,
125
they're still going to call it alveolar.
126
And it's really that and the clinical trials moving forward through the Children's Inchology Group,
127
et cetera, are all doing this.
128
And I think Synovial and Ewings are following suit with that.
129
So it's really boots on the ground.
130
This is happening today, not just some academic ivory tower concept.
131
And I'd like to just highlight the importance of a multidisciplinary team in making the diagnosis.
132
Andy said, very often it's important to have the clinical features
133
and the radiological features together with the pathology to make the diagnosis.
134
And that's really, really important to highlight.
135
I think it's important to highlight the fact that the one thing that these are all mistaken for are melanomas,
136
and melanomas are, you know, they're mistaken for sarcomas.
137
And if you really make that error,
138
you've altered radically a treatment path for a patient.
139
And this is why having a highly experienced sarcoma pathologist confirming what they're seeing is really that important.
140
And what's very interesting is it's very hard,
141
I believe, to have the discussion we're having today
142
because we're talking about at least 80 different diseases that probably break up in six different categories of each one.
143
And we go from probably one of the best understood tumors on the planet,
144
which is the GI stromal tumor,
145
where we understand what mutations go with what drug,
146
to the undifferentiated pleomorphic sarcoma,
147
where we're still doing lots of clinical trials,
148
which we'll get into later.
下载应用
AI 为你说出的每个句子打分
TRENDING
热门
背景与背景信息
在这一段视频中，演讲者是一位经验丰富的外科医生，他分享了关于软组织肉瘤的诊断过程。视频着重强调了医生在患者治疗过程中的关键角色，特别是外科医生在确认病症和制定治疗计划时的重要性。通过深入的病史询问和体检，医生们能够更好地评估可能的病因，为患者提供更有效的治疗。了解这些内容对于医学专业人士和患者都至关重要。
日常交流的五个重要短语
- 病史与体检是我们首先要做的事情。
- 这个肿块变化很快，明显需要处理。
- 我们通常推荐进行平片成像。
- CT扫描在干预前非常重要。
- 了解肿瘤的诊断和分级对治疗至关重要。
逐步跟读指南
对于想要通过此视频提高英语口语能力的学习者，以下是一个有效的逐步跟读（shadowing）指南，帮助您更好地理解和应用视频中的医疗术语及交流方式。
- 反复收听：首先，多次收听该视频，尽量理解每个语句的含义。这一步能帮助您熟悉医生讨论的关键概念及其用语。
- 跟着朗读：在听的同时，尝试跟着演讲者朗读。这可以提高您的英语发音和语调，利用 提高英语发音 的技巧，让您的发音更加清晰。
- 逐句分析：将每个句子拆分，分析其中的重点词汇和表达，如“病史”和“体检”等。这有助于增强您的词汇量，尤其是在医疗领域。
- 录音与回放：尝试录下自己的跟读声音，然后与原视频进行对比。这样可以发现自己的长处与短处，促进更快进步。
- 应用所学：在与他人讨论相关医疗话题时，尝试使用视频中的表达方式。这不仅可以巩固您的记忆，也能提高您的 英语口语练习 效果。
通过这样的练习，您将能够在沟通中更自信，充分利用 英语影子跟读 的方法，提升您的语言技能与交际能力。
什么是跟读法？
跟读法 (Shadowing) 是一种有科学依据的语言学习技巧，最初开发用于专业口译员的培训，并由多语言者Alexander Arguelles博士普及。这个方法简单而强大：您在听英语母语原声的同时立即大声重复——就像是一个延迟1-2秒紧跟说话者的影子。与被动听力或语法练习不同，跟读法强迫您的大脑和口腔肌肉同时处理并模仿真实的讲话模式。研究表明它能显着提高发音准确性，语调，节奏，连读，听力理解和口语流利度——使其成为雅思口语备考和真实英语交流最有效的方法之一。